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Introduction
============

While antipsychotic medications were initially approved based on clinical trials in adult populations, they are commonly prescribed "off-label" in pediatric and geriatric populations \[[@REF1]-[@REF2]\]. In addition, they are increasingly being prescribed to children. Between the 1993 - 1998 and 2005 - 2009 time periods, visits including a prescription for antipsychotics per 100 people increased from 0.24 to 1.83 for children, 0.78 to 3.76 for adolescents, and 3.25 to 6.18 for adults; moreover, antipsychotics were included in 31.1% of youth visits to psychiatrists \[[@REF3]\]. While antipsychotics are among the most effective drugs for the treatment of schizophrenia, mania, or acute psychotic reactions, these medications are often prescribed to children and adolescents for non-FDA approved indications, such as disruptive behaviors and aggression \[[@REF4]-[@REF5]\]. Similarly, antipsychotics are frequently used in the elderly and are prescribed to more than a quarter of Medicare patients in nursing homes, with common conditions including dementia, delirium, and behavioral disturbances \[[@REF2]\]. However, the use of these medications may result in unanticipated adverse events that are specific to the pediatric and geriatric populations \[[@REF6]\]. In our study, we sought to elucidate the differences in adverse events between pediatric, adult, and geriatric populations using the FDA's Adverse Events Reporting System (AERS), a database that has collected information about adverse events since 1998 \[[@REF7]\]. AERS is the FDA's primary tool for post-marketing adverse event surveillance, with over 250,000 adverse event reports annually \[[@REF8]\]. A key strength of the AERS database is the ability to analyze a massive dataset and discover potentially new information regarding drug-related adverse events warranting further investigation. For instance, a recent paper probed the AERS database and found a potential link between amisulpride, cyamemazine, and olanzapine and torsadogenic risk \[[@REF9]\]. Drug manufacturers are required to submit adverse event reports, while healthcare providers can voluntarily submit information.

Materials and methods
=====================

We initially imported AERS quarterly data from January 2004 to September 2008 into the MySQL program (v.1.2.17) (Oracle Corp., Redwood Shores, CA). A table was created that mapped all the various drug names for antipsychotics to a generic name and a drug class (typical vs. atypical) using RxNorm (U.S. National Library of Medicine, Bethesda, MD) and Micromedex® (Truven Health Analytics, Greenwood Village, CO) (Table [1](#TAB1){ref-type="table"}). Next, we joined this table with the AERS drug table (matching by DRUGNAME), the AERS demo table (matching by ISR, which stands for individual safety report), and the AERS REAC table (also matching by ISR). We first retrieved the total number of adverse events associated with each drug name, generic name, and drug class. Next, we created a yearage variable (which standardized all ages in AERS to be reported in years using the AGE and AGE_COD variables) as well as the GNDR_COD variable (which was reported as either "M" or "F") in order to repeat this analysis on the following five subgroups: yearage \< 18 (pediatrics), 18 ≥ yearage ≤ 65 (adults), and yearage \> 65 (geriatrics), GNDR_COD = "M" (males), and GNDR_COD = "F" (females).

Table 1List of Antipsychotic Medications Mapped to Generic Name and Drug ClassDrug NameGeneric NameDrug ClassAbilifyAripiprazoleAtypicalsAripiprazoleAripiprazoleAtypicalsChlorpromazineChlorpromazineTypicalsClozapineClozapineAtypicalsClozarilClozapineAtypicalsDecazateFluphenazineTypicalsDozineChlorpromazineTypicalsFazalcoClozapineAtypicalsFentazinPerphenazine  TypicalsFluphenazineFluphenazineTypicalsFortunanHaloperidolTypicalsGeodonZiprasidoneAtypicalsHaldolHaloperidolTypicalsHaloperidolHaloperidolTypicalsInvegaPaliperidoneAtypicalsKentaceHaloperidolTypicalsLargactilChlorpromazineTypicalsLoxapacLoxapineTypicalsLoxapineLoxapineTypicalsLoxitaneLoxapineTypicalsMellarilThioridazineTypicalsMesoridazineMesoridazineTypicalsMobanMolindoneTypicalsModitenFluphenazineTypicalsNavaneThiothixeneTypicalsNoxeneThiothixeneTypicalsOlanzapineOlanzapineAtypicalsOrapPimozideTypicalsOrmazineChlorpromazineTypicalsPermitilFluphenazineTypicalsPerphenazinePerphenazineTypicalsPimozidePimozideTypicalsPrimazinePromazineTypicalsProlixinFluphenazineTypicalsPromazinePromazineTypicalsQuetiapineQuetiapineAtypicalsRiderilThioridazineTypicalsRisperdalRisperidoneAtypicalsRisperidoneRisperidoneAtypicalsSerenaceHaloperidolTypicalsSerentilMesoridazineTypicalsSeroquelQuetiapineAtypicalsSparinePromazineTypicalsStelazineTrifluoperazineTypicalsSymbyaxOlanzapineAtypicalsThioridazineThioridazineTypicalsThiothixeneThiothixeneTypicalsThorazineChlorpromazineTypicalsTrifluoperazineTrifluoperazineTypicalsTrilafonPromazineTypicalsVesprinTriflupromazineTypicalsZiprasidoneZiprasidoneAtypicalsZyprexaOlanzapineAtypicals

Next, for each drug, we computed the percent of antipsychotic-related adverse events that the drug represented in each population. We then used the z-test of proportions to compare this percent for each drug in the following categories: pediatrics vs. adults, adults vs. geriatrics, and males vs. females. This process was conducted separately for typical and atypical drugs. This resulted in a z-score and a p-value for each comparison, which was then adjusted using a Bonferroni correction for multiple comparisons, making the significance threshold 0.05/26 = 1.92 x 10^-3^.

Afterward, we retrieved the count of each individual adverse event associated with each generic drug, ordered by the frequency of occurrence in each population. We made sure not to include irrelevant or vague side effects in our top results, excluding terms such as "DRUG INTERACTION," "ACCIDENTAL EXPOSURE," and "ACCIDENTAL DRUG INTAKE BY CHILD." In order to compare the frequencies of the different adverse events in the adult, pediatric, and geriatric populations, we conducted a Chi-square test. For each drug, we selected the top five adverse events in adults and added a sixth column that contained the sum of all other adverse events. We chose the top five since this minimized the number of cells in the Chi-square calculation that contained an expected value less than 5, which is not ideal for the Chi-square test. Next, we compared the frequency of these particular adverse events in the adult, pediatric, and geriatric populations using a 3 by 6 Chi-square table with 10 degrees of freedom, and we calculated p-values for each of seven major drugs---aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone---using the R statistical program (v2.12.2). We also used the MedRDA (Medical Directory for Regulatory Activities: International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland) hierarchy to map MedDRA Preferred Terms (the default FDA coding) to high-level terms and determined the frequency of the high-level terms in the three populations.

Next, we took the list of the top five adverse events for the seven drugs in the three populations and used Medical Subject Headings (MeSH terms) to evaluate how many times a particular drug-adverse event combination was indexed in PubMed for the three populations. For instance, for the side-effect "TREMOR" for aripiprazole in the geriatric population, we would have used the following search term: *\"aripiprazole\"\[Substance Name\] AND (\"Aged\"\[Mesh\]) AND tremor*. We then compared the number of reports in AERS and in the literature. For the drug, population, and adverse event combinations that had fewer than five reports in the literature, we manually examined the results to ensure their validity and highlighted the ones that we confirmed to have less than five reports.

Results
=======

A summary of the populations we studied is shown in Table [2](#TAB2){ref-type="table"}.

Table 2Demographics: Summary of the PopulationCategoryValueTotal number of patients61,380Mean age ± SD45.7 ± 20.0Patients where age \< 183,578Patients where age ≥ 18 and age ≤ 6532,660Patients where age \> 657,260Patients where age is not available17,882Male patients27,783Female patients29,780Gender NA (null, unknown, or not specified)3,817

The percentage of antipsychotic-related side effects was often significantly different in the pediatric, adult, and geriatric populations for atypical and typical antipsychotics as shown in Tables [3](#TAB3){ref-type="table"}-[4](#TAB4){ref-type="table"}.

Table 3Comparison of the Number of Adverse Events in Each Population for Atypical AntipsychoticsResults were statistically significant either for pediatrics vs. adults, geriatrics vs. adults, or both. The significance threshold was 0.05/26 = 1.92 x 10^-3^. The p-values that R found to be extremely low are labeled as \"0.\" Items that were statistically significant are in bold.Generic Name% of Adverse Eventsp-value (vs. Adults)Statistical SignificancePediatricsAdultsGeriatricsPediatricsGeriatricsAripiprazole25.99.84.800BothClozapine4.617.313.902.7e^-14^BothOlanzapine16.126.025.600.23PediatricsPaliperidone0.60.60.20.433.5e^-5^GeriatricsQuetiapine24.427.226.12.6e^-5^0.019PediatricsRisperidone23.314.427.500BothZiprasidone5.14.61.90.0770GeriatricsTOTALS100.0100.0100.0 

Table 4Comparison of the Number of Adverse Events in Each Population for Typical AntipsychoticsResults were statistically significant either for pediatrics vs. adults, geriatrics vs. adults, or both. The significance threshold was 0.05/26 = 1.92 x 10^-3^. The p-values that R found to be extremely low are labeled as \"0.\" Items that were statistically significant are in bold.Generic Name% of Adverse Eventsp-value (vs. Adults)Statistical SignificancePediatricsAdultsGeriatricsPediatricsGeriatricsChlorpromazine20.317.112.10.0663.31e^-6^GeriatricsFluphenazine0.35.12.44.3e^-5^4.39e^-6^BothHaloperidol64.956.372.80.00110BothLoxapine2.82.71.90.460.043\--Mesoridazine0.00.20.10.200.27\--Molindone0.90.30.60.0170.018\--Perphenazine0.32.72.30.00380.19\--Pimozide3.41.61.30.00820.17\--Promazine0.62.80.10.00959.39e^-10^GeriatricsThioridazine5.53.93.40.0700.20\--Thiothixene0.04.50.94.9e^-5^1.24e^-10^BothTrifluoperazine0.92.92.00.0170.031\--TOTALS100.0100.0100.0 

Eight antipsychotics were associated with a significant difference in the number of adverse events in the pediatric vs. adult populations, including aripiprazole, clozapine, fluphenazine, haloperidol, olanzapine, quetiapine, risperidone, and thiothixene. Ten antipsychotics were associated with a significant difference in the number of adverse events in the adult vs. geriatric populations, including aripiprazole, chlorpromazine, clozapine, fluphenazine, haloperidol, paliperidone, promazine, risperidone, thiothixene, and ziprasidone. When we compared the distributions of adverse events in the adult population to the pediatric and geriatric populations, Chi-square tests revealed that they were significantly different, as the p-values were 4.33e^-32^, 1.68e^-92^, 2.60e^-35^, 6.96e^-106^, 4.50e^-124^, 3.43e^-65^, and 1.35e^-7^, respectively, for aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone. Tables comparing the number of reports in the literature to those in the AERS database for the top five adverse events in seven major antipsychotics revealed some outliers in the three populations, as evidenced by the reports with less than five cases in the literature (Tables [5](#TAB5){ref-type="table"}-[6](#TAB6){ref-type="table"}).

Table 5Top Adverse Events in the Pediatric PopulationThe searches that have five or less PubMed articles are in bold.Generic NameEvent PediatricsN PediatricsAripiprazoleWEIGHT INCREASED102AripiprazoleTREMOR86AripiprazoleDYSTONIA82AripiprazoleSOMNOLENCE63AripiprazoleEXTRAPYRAMIDAL DISORDER62AripiprazoleOTHERS3,087ClozapineTACHYCARDIA37ClozapineGRANULOCYTOPENIA32ClozapineSOMNOLENCE31ClozapineWHITE BLOOD CELL COUNT DECREASED26ClozapineSEDATION21ClozapineOTHERS1,069HaloperidolSOMNOLENCE35HaloperidolTREMOR23HaloperidolEXTRAPYRAMIDAL DISORDER18HaloperidolMUSCLE SPASMS15HaloperidolNEUROLEPTIC MALIGNANT SYNDROME14HaloperidolOTHERS770OlanzapineWEIGHT INCREASED106OlanzapineAGGRESSION69OlanzapineSUICIDAL IDEATION58OlanzapineABNORMAL BEHAVIOUR46OlanzapineCOMPLETED SUICIDE44OlanzapineOTHERS3,755QuetiapineWEIGHT INCREASED121QuetiapineSUICIDAL IDEATION80QuetiapineTACHYCARDIA74QuetiapineCONVULSION72QuetiapineAGGRESSION70QuetiapineOTHERS4,745RisperidoneAGGRESSION112RisperidoneWEIGHT INCREASED69RisperidoneCONVULSION66RisperidoneSUICIDAL IDEATION65RisperidoneABNORMAL BEHAVIOUR54RisperidoneOTHERS4,015ZiprasidoneDYSTONIA26ZiprasidoneSUICIDAL IDEATION25ZiprasidoneDEPRESSION20ZiprasidoneSUICIDE ATTEMPT20ZiprasidoneWEIGHT INCREASED19ZiprasidoneOTHERS943

Table 6Top Adverse Events in the Geriatric PopulationThe searches that have five or less PubMed articles are in bold.Generic NameEvent GeriatricsN GeriatricsAripiprazoleTREMOR27AripiprazoleNEUROLEPTIC MALIGNANT SYNDROME22AripiprazolePARKINSONISM21AripiprazoleDEATH18AripiprazoleGAIT DISTURBANCE15AripiprazoleOTHERS1,087ClozapineDEATH174ClozapinePNEUMONIA100ClozapinePYREXIA63ClozapineSOMNOLENCE50ClozapineFALL46ClozapineOTHERS3,117HaloperidolAGITATION78HaloperidolCONFUSIONAL STATE75HaloperidolFALL68HaloperidolPYREXIA67HaloperidolDELIRIUM62HaloperidolOTHERS5,196OlanzapineFALL175OlanzapineCONFUSIONAL STATE142OlanzapineDIABETES MELLITUS138OlanzapineCEREBROVASCULAR ACCIDENT107OlanzapinePNEUMONIA100OlanzapineOTHERS9,494QuetiapineFALL155QuetiapineDEATH111QuetiapineCONFUSIONAL STATE107QuetiapineAGITATION103QuetiapinePNEUMONIA91QuetiapineOTHERS7,377RisperidoneSOMNOLENCE161RisperidoneDEATH159RisperidoneCONFUSIONAL STATE152RisperidoneFALL135RisperidoneASTHENIA117RisperidoneOTHERS8,770ZiprasidoneMYOCARDIAL INFARCTION15ZiprasidoneCOMA15ZiprasidoneLOSS OF CONSCIOUSNESS11ZiprasidoneSEDATION11ZiprasidoneAGITATION11ZiprasidoneOTHERS706

Chi-square analysis was performed to compare the actual distribution of adverse events between the different populations for each drug. Seven commonly prescribed antipsychotics are presented in Table [7](#TAB7){ref-type="table"}: aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone.

Table 7Chi-Square AnalysisThe distribution of antipsychotic-related adverse events was compared between the pediatric, adult, and geriatric populations for seven major antipsychotics. For each major antipsychotic drug, adverse events were ordered by their frequency in the adult population, the top five were selected (and the rest designated as \"other\"), and their distribution was compared using the Chi-square test. The resultant p-value is in the final column.Generic NameEvent AdultsN PedsN AdultsN Geriatricsp-ValueAripiprazoleDIABETES MELLITUS1128810 AripiprazoleWEIGHT INCREASED10223513 AripiprazoleINSOMNIA1122712 AripiprazoleTREMOR8617727 AripiprazoleANXIETY131584 AripiprazoleOTHERS3,25914,4911,1244.3e^-32^ClozapineGRANULOCYTOPENIA3261127 ClozapineLEUKOPENIA1139020 ClozapinePYREXIA1637663 ClozapineDEATH0342174 ClozapineTACHYCARDIA3730917 ClozapineOTHERS1,12029,6693,2491.7e^-92^HaloperidolDIABETES MELLITUS02058 HaloperidolNEUROLEPTIC MALIGNANT SYNDROME1419644 HaloperidolSOMNOLENCE3514841 HaloperidolPYREXIA1014767 HaloperidolHYPERTENSION212812 HaloperidolOTHERS81414,5285,3742.6e^-35^OlanzapineDIABETES MELLITUS422,197138 OlanzapineWEIGHT INCREASED1061,46464 OlanzapineHYPERTENSION2190656 OlanzapinePANCREATITIS2786543 OlanzapineDIABETES MELLITUS NON-INSULIN-DEPENDENT672021 OlanzapineOTHERS3,87662,4609,8347.0e^-106^QuetiapineDIABETES MELLITUS392,06655 QuetiapinePANCREATITIS1687128 QuetiapineWEIGHT INCREASED12166218 QuetiapineSOMNOLENCE7052879 QuetiapineDIZZINESS4147375 QuetiapineOTHERS4,87548,3147,6894.5e^-124^RisperidoneDIABETES MELLITUS2061434 RisperidoneWEIGHT INCREASED6939015 RisperidoneDEPRESSION4632741 RisperidoneSOMNOLENCE47292161 RisperidoneNEUROLEPTIC MALIGNANT SYNDROME1926237 RisperidoneOTHERS4,18032,3009,2063.4e^-65^ZiprasidoneDIABETES MELLITUS42433 ZiprasidoneWEIGHT INCREASED191732 ZiprasidoneANXIETY151165 ZiprasidoneDEPRESSION201053 ZiprasidoneINSOMNIA121046 ZiprasidoneOTHERS98310,3167501.3e^-7^

The top five adverse events for less common drugs are listed in Table [8](#TAB8){ref-type="table"}.

Table 8Number and Type of Events in Each Population for Minor DrugsGeneric NameEvent PediatricsNEvent AdultsNEvent GeriatricsNChlorpromazineDRUG EXPOSURE DURING PREGNANCY12DIABETES MELLITUS100WEIGHT DECREASED17ChlorpromazineSOMNOLENCE9VOMITING59DIARRHOEA16ChlorpromazineAGGRESSION7NEUROLEPTIC MALIGNANT SYNDROME52DEHYDRATION15ChlorpromazineDRUG INEFFECTIVE6CONVULSION51PNEUMONIA14ChlorpromazineWEIGHT INCREASED6PYREXIA50SEPSIS13FluphenazineARRHYTHMIA1DIABETES MELLITUS26CONFUSIONAL STATE6FluphenazineMYOCARDITIS1HYPERTENSION22URINARY TRACT INFECTION5FluphenazinePYREXIA1WEIGHT INCREASED17SOMNOLENCE5FluphenazineNA0HYPONATRAEMIA17SEDATION5FluphenazineNA0HYPOTENSION16TACHYCARDIA3LoxapinePROTHROMBIN LEVEL DECREASED3PYREXIA15DYSPHAGIA5LoxapineCONGENITAL GENITOURINARY ABNORMALITY2SEPSIS11CONFUSIONAL STATE4LoxapineCRYPTORCHISM2AGITATION10DEPRESSED LEVEL OF CONSCIOUSNESS4LoxapineDRUG EXPOSURE DURING PREGNANCY2LACTIC ACIDOSIS10SOMNOLENCE3LoxapineRENAL CYST2BLOOD CREATINE PHOSPHOKINASE INCREASED9ANAEMIA3MesoridazineNA0AGGRESSION4MALAISE1MesoridazineNA0EXCESSIVE MASTURBATION3STOMATITIS1MesoridazineNA0RASH PAPULAR3TARDIVE DYSKINESIA1MesoridazineNA0SKIN ULCER3NA0MesoridazineNA0RASH2NA0MolindoneNEUROLEPTIC MALIGNANT SYNDROME2PRESCRIBED OVERDOSE3HAEMOGLOBIN DECREASED3MolindoneMYOSITIS1CONVULSION3MYELOID LEUKAEMIA3MolindonePYREXIA1DIABETES MELLITUS NON-INSULIN-DEPENDENT2PLATELET COUNT DECREASED3MolindoneVIRAL MYOSITIS1ANGER2WHITE BLOOD CELL COUNT INCREASED3MolindoneRASH1ABDOMINAL DISTENSION2TARDIVE DYSKINESIA3PaliperidoneNEUROLEPTIC MALIGNANT SYNDROME10GALACTORRHOEA30DYSPNOEA4PaliperidoneHEADACHE9EXTRAPYRAMIDAL DISORDER23DEEP VEIN THROMBOSIS3PaliperidoneCONFUSIONAL STATE8AKATHISIA17TREMOR3PaliperidonePALPITATIONS8OEDEMA PERIPHERAL17RENAL FAILURE3PaliperidoneDYSTONIA6DYSTONIA12CONFUSIONAL STATE2PerphenazineNA0VOMITING11DRUG INEFFECTIVE6PerphenazineNA0COMPLETED SUICIDE10HYPOTENSION5PerphenazineNA0DIABETES MELLITUS10INSOMNIA4PerphenazineNA0DRUG INTERACTION8CEREBRAL INFARCTION4PerphenazineNA0DRUG INEFFECTIVE8AGRANULOCYTOSIS3PimozideWEIGHT INCREASED4CARDIAC ARREST12COMA4PimozideDIARRHOEA4SUICIDE ATTEMPT8MEDICATION ERROR4PimozideRECTAL HAEMORRHAGE4DRUG INTERACTION7TOXIC SKIN ERUPTION3PimozideSOMNOLENCE3OVERDOSE6THROMBOCYTOPENIA3PimozideANOREXIA2ANXIETY6FALL2PromazineNEONATAL DIABETES MELLITUS1DIABETES MELLITUS33DRUG INTERACTION2PromazinePREMATURE BABY1PANCREATITIS15METHYLMALONIC ACIDURIA1PromazineDEATH1MYOCARDIAL INFARCTION15MUSCLE RIGIDITY1PromazineDIAPHRAGMATIC HERNIA1BLOOD PRESSURE DECREASED14CONFUSIONAL STATE1PromazinePULMONARY HYPOPLASIA1MYOCARDITIS14PLATELET COUNT INCREASED1ThioridazineNAUSEA8HEADACHE32CONFUSIONAL STATE9ThioridazineANOREXIA8DIZZINESS29HYPERGLYCAEMIA8ThioridazineVOMITING5DEPRESSION25ANXIETY7ThioridazineACHOLIA5ANXIETY24BACK PAIN7ThioridazineAGGRESSION5WEIGHT DECREASED22DEPRESSION6ThiothixeneNA0DIABETES MELLITUS63DYSPNOEA4ThiothixeneNA0WEIGHT INCREASED56CEREBROVASCULAR ACCIDENT3ThiothixeneNA0HEADACHE33NAUSEA3ThiothixeneNA0PANCREATITIS33TARDIVE DYSKINESIA3ThiothixeneNA0CHEST PAIN31ANTICHOLINERGIC SYNDROME2TrifluoperazineSEXUAL OFFENCE1DIABETES MELLITUS32CEREBROVASCULAR ACCIDENT6TrifluoperazineCONVULSION1INSOMNIA16CEREBRAL ATROPHY5TrifluoperazineDEPRESSION1DEPRESSION13TRANSIENT ISCHAEMIC ATTACK5TrifluoperazineINJURY1DIABETIC KETOACIDOSIS12TREMOR5TrifluoperazineMEDICATION ERROR1PANCREATITIS12MYOCARDIAL INFARCTION4

The top five adverse events for the seven major antipsychotics mapped to MedDRA high-level terms are listed in Table [9](#TAB9){ref-type="table"}.

Table 9Number and Type of Events in Each Population for Major Drugs Organized by MedDRA® High-Level TermsNEC: not elsewhere classifiedGenericEvent PediatricsNEvent AdultsNEvent GeriatricsNAripiprazoleNeurological signs and symptoms NEC196Neurological signs and symptoms NEC577Neurological signs and symptoms NEC56AripiprazoleDyskinesias and movement disorders NEC172Dyskinesias and movement disorders NEC445General signs and symptoms NEC36AripiprazoleDisturbances in consciousness NEC143Anxiety symptoms420Muscle tone abnormal33AripiprazolePhysical examination procedures133General signs and symptoms NEC408Dyskinesias and movement disorders NEC33AripiprazoleGeneral signs and symptoms NEC117Physical examination procedures402Parkinson\'s disease and parkinsonism29ClozapineDisturbances in consciousness NEC78White blood cell analyses1,222General signs and symptoms NEC193ClozapineWhite blood cell analyses56Neutropenias1,137Death and sudden death192ClozapineNeutropenias52Disturbances in consciousness NEC952Disturbances in consciousness NEC145ClozapineRate and rhythm disorders NEC42General signs and symptoms NEC887Lower respiratory tract and lung infections121ClozapineNeurological signs and symptoms NEC39Neurological signs and symptoms NEC831Lower respiratory tract infections NEC117HaloperidolDisturbances in consciousness NEC51Disturbances in consciousness NEC471Neurological signs and symptoms NEC246HaloperidolMedication errors due to accidental exposures50Neurological signs and symptoms NEC425Disturbances in consciousness NEC162HaloperidolMuscle tone abnormal39General signs and symptoms NEC381General signs and symptoms NEC141HaloperidolDyssomnias35Breathing abnormalities278Ventricular arrhythmias and cardiac arrest140HaloperidolDyskinesias and movement disorders NEC33Liver function analyses274Anxiety symptoms126OlanzapineSuicidal and self-injurious behavior198Diabetes mellitus (incl subtypes)2,403Disturbances in consciousness NEC374OlanzapinePhysical examination procedures150Physical examination procedures2,016Neurological signs and symptoms NEC355OlanzapineNeurological signs and symptoms NEC134General signs and symptoms NEC1,556General signs and symptoms NEC303OlanzapineBehavior and socialization disturbances130Disturbances in consciousness NEC1,551Non-site specific injuries NEC201OlanzapineGeneral signs and symptoms NEC126Neurological signs and symptoms NEC1,312Liver function analyses182QuetiapineSuicidal and self-injurious behavior235Diabetes mellitus (incl subtypes)2,432Neurological signs and symptoms NEC331QuetiapineNeurological signs and symptoms NEC205General signs and symptoms NEC1,531Disturbances in consciousness NEC292QuetiapinePhysical examination procedures178Neurological signs and symptoms NEC1,514General signs and symptoms NEC221QuetiapineGeneral signs and symptoms NEC172Disturbances in consciousness NEC1,386Non-site specific injuries NEC181QuetiapineDisturbances in consciousness NEC170Suicidal and self-injurious behavior1,120Circulatory collapse and shock170RisperidoneBehavior and socialization disturbances217General signs and symptoms NEC966Disturbances in consciousness NEC441RisperidoneSuicidal and self-injurious behavior202Disturbances in consciousness NEC870Neurological signs and symptoms NEC351RisperidoneNeurological signs and symptoms NEC194Neurological signs and symptoms NEC867Asthenic conditions245RisperidoneGeneral signs and symptoms NEC128Diabetes mellitus (incl subtypes)713General signs and symptoms NEC223RisperidoneDyskinesias and movement disorders NEC121Physical examination procedures622Death and sudden death190ZiprasidoneSuicidal and self-injurious behavior61Neurological signs and symptoms NEC319Disturbances in consciousness NEC41ZiprasidoneGeneral signs and symptoms NEC53General signs and symptoms NEC300Ventricular arrhythmias and cardiac arrest41ZiprasidoneBehavior and socialization disturbances52Anxiety symptoms283Neurological signs and symptoms NEC35ZiprasidoneNeurological signs and symptoms NEC47Diabetes mellitus (incl subtypes)281Dyskinesias and movement disorders NEC24ZiprasidoneAnxiety symptoms41Disturbances in consciousness NEC280Ischemic coronary artery disorders23

Discussion
==========

Overall, it was evident that both the frequencies and types of adverse events found in the adult population do not fit the distribution found in the pediatric or geriatric populations. As has been seen in prior studies, diabetes mellitus was frequently the most commonly reported adverse event in adults \[[@REF10]\], but this was not the case for either the pediatric or geriatric populations. One possible explanation for this is that since adults are more likely than children to have impaired fasting glucose in the first place (often due to a longer exposure to certain physiolologic factors, such as obesity and a sedentary lifestyle), they may be more predisposed to developing this complication. On the other hand, "weight increase" was frequently a top-five adverse effect for the major antipsychotic medications in children, consistent with prior meta-analyses \[[@REF11]\]. Children were also more likely to exhibit side effects, such as "aggression," "abnormal behavior," and "suicidality," cognitive effects that may be seen more often in the developing brain. In particular, suicide attempts have previously been linked to antipsychotics in children with the AERS database \[[@REF12]\]. For the geriatric population, neurological side effects, such as "confusional state" and "somnolence," figured more prominently. This suggests that the elderly, who are predisposed to neurological problems, may be more severely affected by the neurological sequelae of antipsychotics. In fact, the Clinical Antipsychotic Trials of Intervention Effectiveness--Alzheimer\'s Disease (CATIE-AD) trial, studying elderly patients with Alzheimer\'s disease, showed that atypical antipsychotics were associated with worsening cognitive function comparable to an additional year\'s worth of cognitive decline compared to placebo \[[@REF13]\].

Although we also analyzed differences in high-level terms between pediatric, adult, and geriatric populations, we realized that going to the next higher level grouping for MedDRA terms was not particularly illustrative. For instance, how does one distinguish "Neurological signs and symptoms" from "Disturbances in consciousness," and what exactly constitutes "General signs and symptoms?" These were among the most commonly reported high-level terms.

Our analysis of the literature revealed that there were adverse events that frequently had reports in AERS; yet, these events were not commonly mentioned in the literature. In the adult population, amongst the top five adverse events for the seven major antipsychotics, only pancreatitis in patients taking quetiapine had fewer than five reports in the literature. The analyses for the pediatric and geriatric populations generated comparatively more adverse events that were not commonly found in the literature. The result for quetiapine in the geriatric population is interesting, given reports of its association with pneumonia \[[@REF14]\].

The limitations of the FDA AERS database include the lack of information on the number of individuals taking the various antipsychotic medications in each age group, which could have served as a "denominator" in our study. Due to this lack of a denominator, when comparing the total number of adverse events across the pediatric, adult, and geriatric populations, it was difficult to determine whether variations in the relative distribution of adverse events between the three age groups was truly due to differences in the rate of adverse events rather than simply variations in prescription frequency. For instance, this could be related to prescription trends or when the medications were released. Fortunately, the issue of a denominator was not problematic when comparing the particular side effect profile between the three populations for any given drug. Another issue is the fact that the correlation of a particular medication with an adverse event does not necessarily prove causation. For instance, an individual who is prone to a particular adverse event may be more likely to take an antipsychotic. Another potential problem is recall bias, as a physician who knows a patient is taking a given drug may be more likely to report adverse events that are widely known to be associated with that drug. Nevertheless, the sheer volume of the AERS database and its vast scope make it a useful tool for studying drug-related adverse events.

Conclusions
===========

Overall, we were able to show that there are significant differences in both the numbers and types of adverse events between the pediatric, adult, and geriatric populations. In addition, this study offers a number of drug and adverse event combinations for follow-up analysis. Given the fact that these medications were overwhelmingly tested on the adult population and are commonly prescribed off-label, it is imperative that clinicians remain mindful of these differences when prescribing these medications in populations for whom the drugs were never formally tested.
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